Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Issue 1 (1st January 2003)

• Record Type: Journal Article
• Authors: Gottstein, R; Cooke, R W I
• Is Part Of: Archives of disease in childhood. Volume 88:Issue 1(2003)
• Page Start: F6
• Page End: F10
• Publication Date: 2003-01-01
• Subjects: intravenous immunoglobulin -- rhesus haemolytic disease -- ABO incompatibility -- exchange transfusion; IVIG, intravenous immunoglobulin -- HDIVIG, high dose IVIG -- HDN, haemolytic disease of the newborn -- RR, relative risk -- RD, risk difference -- WMD, weighted mean difference -- CI, confidence interval -- NNT, number needed to treat; Infants -- Diseases -- Periodicals; Newborn infants -- Diseases -- Periodicals; Fetus -- Diseases -- Periodicals; 618.920105
• DOI: 10.1136/fn.88.1.F6
• Languages: English
• ISSNs: 1359-2998

Abstract

Abstract : Objectives: To assess the effectiveness of high dose intravenous immunoglobulin (HDIVIG) in reducing the need for exchange transfusion in neonates with proven haemolytic disease due to Rh and/or ABO incompatibility. To assess the effectiveness of HDIVIG in reducing the duration of phototherapy and hospital stay. Design: Systematic review of randomised and quasi-randomised controlled trials comparing HDIVIG and phototherapy with phototherapy alone in neonates with Rh and/or ABO incompatibility. Results: Significantly fewer infants required exchange transfusion in the HDIVIG group (relative risk (RR) 0.28 (95% confidence interval (CI) 0.17 to 0.47); number needed to treat 2.7 (95% CI 2.0 to 3.8)). Also hospital stay and duration of phototherapy were significantly reduced. Conclusion: HDIVIG is an effective treatment.